Top Ten Contributions of Pediatric Hematology/Oncology to the Diagnosis and Treatment of Acute Lymphoblastic Leukemia.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
received:
04
06
2023
accepted:
02
08
2023
medline:
30
10
2023
pubmed:
27
10
2023
entrez:
27
10
2023
Statut:
ppublish
Résumé
Monumental progress has occurred in the diagnosis and treatment of childhood acute lymphoblastic leukemia dating back to the classic paper of Farber and colleagues in 1948. This historical review from the perspective of an individual, familiar with many of the waystations on this superhighway, will offer an admittedly personal review of the top 10 major contributions to the field. Fortunately, there have been many more additional advances beyond these 10 as we have witnessed an impressive improvement in overall survival from a few months 75 years ago to a cure rate of 85% in the world's more advanced countries. Other workers in the field assuredly would create a different list and ranking of these advances but the takeaway summation of the make-up and order of these lists is that advances have yielded improved and prolonged responses, a rational understanding of factors, both clinical and biological, that predict response and prognosis, the application of those factors to tailor therapy's intensity and duration to those factors and to discover and design modalities and targets of therapy that target our much more complete understanding of this most common malignancy of infants and children. On a very personal note, I vividly recall an early, ill-advised decision to devote my academic career to hematology/oncology, with one glaring exception, acute lymphoblastic leukemia, and other malignancies. The stark realities of clinical practice and the harsh unmet needs and mostly unanswered challenges redirected my path that resulted in participation in many of these advances, making my own journey so gratifying and that of most of our patients so favorable.
Identifiants
pubmed: 37889043
doi: 10.1097/MPH.0000000000002758
pii: 00043426-202311000-00001
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
429-435Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The author declares no conflict of interest.
Références
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.
Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med. 1948;238:787–793.
Miller DR. A tribute to Sidney Farber—the father of modern chemotherapy. Br J Haematol. 2006;134:20–26.
Bagri NK, Ramanan A, Ramanan AV. Dr. Yellapragada SubbaRow—the forgotten figure in the history of methotrexate. Rheumatology. 2023;62:1364–1365.
Frei E, Karon M, Levin RH, et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood. 1965;26:642–656.
Riehm H, Reiter A, Schrappe M, et al. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Paediatr. 1987;199:151–160.
O’Leary M, Krailo M, Anderson JR, et al. Progress in childhood cancer: 50 years of research collaboration: a report from the Children’s Oncology Group. Semin Oncol. 2008;35:484–493.
Leiken S, Brubaker C, Hartmann J, et al. The use of combination therapy in leukemia remission. Cancer. 1969;24:427–432.
Aur RJA, Simone J, Hustu O, et al. Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood. 1971;37:272–281.
Hunger S, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541–52.
Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;325:1330–1336.
Miller DR, Leiken S, Albo V, et al. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG 141. A report from Children's Cancer Study Group. Cancer. 1983;51:1041–1049.
Miller DR, Sonley M, Karon M, et al. Additive therapy in the maintenance of remission in acute lymphoblastic leukemia of childhood. Cancer. 1974;14:508–517.
Miller DR, Coccia PF, Bleyer WA, et al. Early response to induction therapy predicts early and late relapse in childhood acute lymphoblastic leukemia. J Clin Oncol. 1989;7:1807–1815.
Sallan SE, Katz H, Pesando J, et al. Cell surface antigens: prognostic implications in childhood acute lymphocytic leukemia. Blood. 1980;55:395–402.
Gaynon PS, Bleyer WA, Steinherz PG, et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol. 1990;18:273–279.
Schaink A, Higgins C, Belsch E, et al. Minimal residual disease evaluation in childhood acute lymphoblastic leukemia: a clinical evidence review. Ont Health Technol Assess Ser. 2016;16:1–52.
Nesbit ME, Sather HN, Robison LL, et al. Randomized study of 3 years versus 5 years of chemotherapy in childhood acute lymphoblastic leukemia. J Clin Oncol. 1983;1:308–316.
Miller DR, Leiken SL, Albo VC, et al. Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: a report from the. Childrens Cancer Study Group. 1989;7:316–325.
Iacobucci H, Kimura S, Mullighan CG. Biologic and therapeutic implications of genomic alterations in acute lymphoblastic leukemia. J Clin Med 2021;10:3792.
Chen M, Zhu Y, Lin Y, et al. Use of tyrosine kinase inhibitors for pediatric Ph chromosome-positive ALL: a systemic review and relationship. Br Med J. 2021;11:e042814.
Section on hematology/oncology. Policy statement on guidelines for pediatric cancer centers. Pediatrics. 2004;113:1833–1835.
Look AT, Roberson PK, Williams DL, et al. Prognostic importance of blast call DNA content in childhood acute lymphoblastic leukemia. Blood. 1985;65:1079–1086.
Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477–4489.
Steinherz PG, Gaynon P, Miller DR, et al. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the “New York” regimen. A report from the Children's Cancer Study Group. J Clin Oncol. 1986;4:744–752.
Chessells JM, Bailey C, Wheeler K, et al. Bone marrow transplantation for high-risk childhood lymphoblastic leukaemia in first remission: experience in MRC UKALL X. Lancet. 1992;340:565–568.
Boettcher M, Joechner A, Ziduo L, et al. Development of CAR-T cell therapy in children-a comprehensive review. J Clin Med. 2022;11:2159.
Muffly L, Curran E. Pediatric-inspired protocols for adults with acute lymphoblastic leukemia Are the results bearing fruit. Educational Book, ASH; 2019.
Chaganti RSK, Miller DR, Meyers PA, et al. Cytogenetic evidence for the intrauterine origin of acute leukemia in monozygotic twins. N Engl J Med. 1979;300:1032–1033.
Greaves M. A causal mechanism of childhood acute lymphoblastic leukaemia. Nat Rev Cancer. 2018;18:471–84.